Neal James R 4
4 · PALISADE BIO, INC. · Filed Feb 13, 2024
Insider Transaction Report
Form 4
Neal James R
Director
Transactions
- Exercise/Conversion
Restricted Stock Units
2024-02-09−5,100→ 0 total→ Common Stock (5,100 underlying) - Exercise/Conversion
Common Stock, par value $0.01
2024-02-09+5,100→ 5,100 total - Exercise/Conversion
Common Stock, par value $0.01
2024-02-09+5,820→ 10,920 total - Exercise/Conversion
Restricted Stock Units
2024-02-09−5,820→ 0 total→ Common Stock (5,820 underlying) - Exercise/Conversion
Common Stock Options
2024-02-09+12,160→ 12,160 totalExercise: $1.60From: 2023-06-11Exp: 2033-06-11→ Common Stock (12,160 underlying) - Exercise/Conversion
Common Stock Options
2024-02-09+6,880→ 6,880 totalExercise: $0.59From: 2023-11-21Exp: 2033-11-21→ Common Stock (6,880 underlying) - Exercise/Conversion
Common Stock Options
2024-02-09−12,160→ 0 totalExercise: $1.60From: 2023-06-11Exp: 2033-06-11→ Common Stock (12,160 underlying) - Exercise/Conversion
Common Stock Options
2024-02-09−6,880→ 0 totalExercise: $0.59From: 2023-11-21Exp: 2033-11-21→ Common Stock (6,880 underlying)
Footnotes (8)
- [F1]Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units granted on June 11, 2023, resulting from the full accelerated vesting in connection with Reporting Person's resignation from the Issuer's Board of Directors.
- [F2]Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units granted on November 21, 2023, resulting from the full accelerated vesting in connection with Reporting Person's resignation from the Issuer's Board of Directors.
- [F3]This restricted stock unit was granted on June 11, 2023 and pursuant to the issuance upon full vesting as described in Footnote 1, is no longer outstanding.
- [F4]This restricted stock unit was granted on November 21, 2023 and pursuant to the issuance upon full vesting described in Footnote 2, is no longer outstanding.
- [F5]Each restricted stock unit represents the right to receive one share of common stock.
- [F6]Each option represents the right to purchase one share of common stock at the exercise price.
- [F7]Represents the modification of the option granted on June 11, 2023, resulting in (i) immediate vesting in full of the outstanding grant and (ii) extension of the exercise period until the expiration date in connection with Reporting Person's resignation from the Issuer's Board of Directors.
- [F8]Represents the modification of the option granted on November 21, 2023, resulting in (i) immediate vesting in full of the outstanding grant and (ii) extension of the exercise period until the expiration date in connection with Reporting Person's resignation from the Issuer's Board of Directors.